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A Ab bs st tr ra ac ct t
Genome-wide association scans are beginning to identify risk alleles for a number of complex
diseases and traits. Essential hypertension looked as though it would be an exception to this
trend after the Wellcome Trust Case Control Consortium data were published in 2007.
However, more recent scans and meta-analyses have reversed the fortunes of essential
hypertension. A number of loci have been identified, including a new antihypertensive drug target
in the guise of the serine/threonine kinase SPAK. This kinase forms part of a novel kinase cascade
that regulates the NCCT (Na+/Cl– co-transporter; SLC12A3) in the kidney and is defective in a
rare Mendelian hypertension syndrome (Gordon’s syndrome). Genome-wide scans are also being
used to look for alleles to predict individual response to antihypertensive drugs and their risk of
causing side-effects. The results of these are expected in the near future and may finally deliver
the long-awaited goal of personalized drug therapy for hypertensive patients.
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I In nt tr ro od du uc ct ti io on n
The idea that blood pressure (BP) and (by definition) hyper-
tension are polygenic traits arose half a century ago from the
famous debate between George Pickering and Robert Platt
about the nature of the frequency distribution of BP [1].
Many epidemiological studies have subsequently confirmed
the heritability of BP; however, its inheritance is not
Mendelian as Platt believed, but rather complex. In fact the
major diseases of industrialized societies, including obesity,
diabetes, and coronary artery disease (CAD), have complex
genetics. The favored model for these complex diseases is
often referred to as the ‘common disease-common variant’
hypothesis (CD-CV), in which each susceptibility locus in the
human genome for a complex disease is explained by a
single (or a handful of) gene variant(s) or allele(s) [2]. This
relatively simple allelic architecture, of many susceptibility
genes but few variants of each gene, has not been extensively
tested. Some loci do fall neatly into this classification, such
as the ApoE locus in CAD [3] and PPARG in type 2 diabetes
[4], which have single coding variants. However, others,
such as the NOD2 locus in Crohn’s disease [4] or the calpain
10 (CAPN10) locus in type 2 diabetes [5], cannot be
explained so simply. To date, the problem for essential
hypertension has been more fundamental, with a difficulty
in confidently identifying any susceptibility loci. Linkage-
based approaches have been used, but they require family
structures that are difficult to recruit in very large numbers.
Even when linked loci have been identified [6], there
remains the formidable task of finding a functional variant
within a locus that perhaps covers a substantial fraction of a
chromosome and contains hundreds of genes.
T Th he e   h hy yp pe er rt te en ns si io on n   g ge en no om me e- -w wi id de e   a as ss so oc ci ia at ti io on n   s st tu ud dy y
c co om me es s   o of f   a ag ge e
In contrast to the difficulties of using linkage, association
studies are ideally suited for chasing putative CD-CV gene
variants. Initially, association studies explored individual
candidate genes, but key genomic discoveries andtechnological advances in the last decade have changed this.
First was the discovery of widespread genomic variation in
the form of single nucleotide polymorphisms (SNPs). These
occur on average every few hundred bases along the genome,
and their mapping under the Hapmap project has provided a
detailed framework of genomic variation across the entire
genome [7]. Second has been the technology to genotype
hundreds of thousands of SNPs on a single ‘chip’. Together,
these have led to the genome-wide association study
(GWAS) becoming commonplace as a method to dissect
complex diseases and traits. The problem with association
studies has, however, always been their poor record of repro-
ducibility [8]. The reasons for this are manifold, including
poor matching of cases and controls; hidden stratification in
the populations; allelic and genetic heterogeneity; differ-
ences in environmental effects between populations;
different attributable risks to an allele in different popula-
tions; and differences in an allele’s frequency between
populations. The lack of power in many studies has also been
an important contributor to both false-negative and false-
positive GWAS results.
Two GWAS in hypertension were published during 2007,
but these were disappointing. The Framingham Heart Study
(FHS) reported on 1,327 individuals whose BP had been
sampled longitudinally in the Framingham community
project [9], and the Wellcome Trust Case Control Consor-
tium (WTCCC) reported results from 2,000 Northern
European subjects with hypertension [10]. The WTCCC used
a denser SNP coverage of the genome than the FHS (300K
versus 100K), but lacked BP data to look for quantitative
trait effects. Nevertheless, neither study could identify SNPs
that achieved genome-wide statistical significance
(P <5×1 0 –7) - a necessary cut-off because of the multiple
testing involved. A handful of SNPs did achieve P values of
<10–5 in both studies, but none of these SNPs were common
to the two studies. With hindsight, there were difficulties in
the WTCCC, especially in its controls, which were not
specifically selected for BP. Instead, they represented a
common set of controls used for all seven common diseases
considered by the WTCCC, so it is likely that a significant
minority of the controls were in fact hypertensive. The chip
used in the WTCCC (itself substantially better than the 100K
used by the FHS) also poorly tagged some of the candidates
previously reported to associate or link with hypertension.
This was certainly the case for the WNK1 gene (With No
K-lysine deficient protein kinase 1), which has attracted a lot
of attention in the past few years. Mutations in this novel
serine/threonine kinase, along with WNK4, have provided
the molecular basis for Gordon’s syndrome, a rare Mendelian
form of familial hypertension and hyperkalemia [11]. The UK
BRItish Genetics of HyperTension (BRIGHT) consortium
initially reported association of the WNK1 promoter with BP
in essential hypertension [12], a result that was replicated in
a longitudinal study of BP in childhood [13]. The poor
tagging of WNK1 has improved with newer chips, and
obviously the problem can be tackled by imputation. Never-
theless, the WNK genes have not emerged as candidates
from subsequent GWAS.
The FHS and WTCCC GWAS results were disappointing
since they suggested that hypertension really could lack
susceptibility alleles with effect sizes as large as those in
other complex diseases such as type 2 diabetes and obesity
(odd ratios 1.2-1.5) [14,15]. An attempt was made to replicate
the six SNPs that achieved highest significance in
hypertension (5 × 10–7 < P <1 0 –5) in the WTCCC sample, by
using 12,593 individuals from the Family Blood Pressure
Program [16]. In fact, they could only replicate one of them
(rs1937506), and although the effect on systolic BP was
large, it went in opposite directions in different ethnic sub-
groups (Americans of Hispanic versus European ancestry).
There is also the issue that this SNP sits in a 500K bp gene
desert with no obvious gene sitting in linkage disequilibrium
(LD) with it.
In 2009, the first GWAS reporting SNP hits that achieve
genome-wide statistical significance were published [17,18].
Their replication outside of the primary discovery cohort
gives added reassurance that these may be true positive hits.
The KORA (Kooperative Gesundheitsforschung in der
Region Augsburg) GWAS [17] was based on a south German
cohort and identified a SNP upstream of the CDH13 gene,
rs11646213, that encodes the T-cadherin adhesion molecule.
This membrane-bound receptor is involved in angiogenesis
and can function as an adiponectin receptor, so it is
biologically plausible. Importantly, this SNP was replicated
in two further European cohorts, although not in the UK
BRIGHT cohort. The CDH13 gene was also highlighted in
the secondary analysis of the 100K FHS GWAS (rs3096277)
[9], so it merits close follow-up.
The second GWAS to report a genome-wide significant hit
used an Amish cohort and identified a novel candidate gene
in the form of STK39, a serine/threonine kinase called SPAK
(STE20/SPS1-related proline- and alanine-rich kinase) [18].
This is an intriguing result for two reasons. Firstly, SPAK
and related kinases are known to regulate the activity of
cation/chloride transporters, including the Na+/Cl– co-
transporter NCCT, in the distal convoluted tubule (DCT) of
the kidney [19]. SPAK appears to activate NCCT by phos-
phorylating key residues in its amino-terminal region, so
functional SPAK variants will affect salt uptake by the DCT
and hence BP. Secondly, SPAK itself is a phosphorylation
target for upstream WNK kinases, mutations of which are
now known to form the molecular basis for Gordon’s
syndrome. So this very rare Mendelian BP syndrome of salt-
dependent hypertension and hyperkalemia has led to the
discovery of a regulatory phosphorylation cascade that
harbors a polygenic BP trait. This offers the real prospect
that blocking one of these kinases could lead to a novel class
of antihypertensive drug. This is perhaps ironic given that
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In common with recent experience from other complex
diseases and traits, combining datasets in meta-analyses
gives the power to robustly probe their allelic structure. The
Global BPgen consortium has recently reported the results of
a GWAS meta-analysis using 34,433 subjects, which is an
order of magnitude larger than any of the single-cohort
GWAS preceding it [20]. They have identified no less than
eight loci with obvious candidate genes and some of these
hits (in the region of CYP17A1, CYP1A2 and FGF5) carry very
high levels of significance (P <1 0 –20) indeed. The hits
identified were the same whether BP was analyzed as a
quantitative trait or the dichotomous trait of hypertension,
which may have surprised some and reassured others. How-
ever, it is also notable that these hits do not include any of
the genome-wide significant hits reported elsewhere. Global
BPgen is clearly setting the new benchmark for GWAS in
hypertension. A second consortium, the CHARGE (Cohorts
for Heart and Aging Research in Genomic Epidemiology)
consortium, is set to publish its own meta-analysis shortly. It
has a slightly larger cohort of 38,000 [21] and it is hoped
there will be overlap of its hits with Global BPgen. Only time
will confirm whether or not this is the case.
R Re ef fi in ni in ng g   t th he e   G GW WA AS S   l le ea ad ds s
In comparison to the problems of unraveling essential
hypertension, the rare Mendelian forms of high and low BP
are now relatively well understood, with causative mutations
identified in some 20 different genes [22]. Most of these
genes affect salt handling by the kidney and can have a large
effect, in the range of several tens of millimeters of mercury,
on the BP of affected individuals. However, functional
variants in these genes are probably not a major influence on
the BP within the general population. Hence, the re-
sequencing of the genes for three of these Mendelian forms
of BP (SLC12A3, SLC12A1 and KCNJ1) in the FHS cohort
identified known or putative functional mutations in just 49
of the 3,095 subjects screened [23]. The mutations did sub-
stantially affect the BP of the carriers (up to 6-8 mmHg), but
all had a frequency of <1/2,000. So, it seems that for essen-
tial hypertension the CV-CD hypothesis is still largely intact.
A striking feature of the SNPs identified in GWAS in
complex diseases over the past few years is how small a
proportion of disease variability is explained by them. So,
the problem for the future will be to identify hypertension
alleles that may be rare, possibly poorly penetrant and
certainly of low attributable risk (odds ratios <1.2 and
accounting for <1 mmHg of BP). The effects of some of these
alleles will also be conditional on interactions with other
alleles and environmental factors such as salt loading. An
insight into this problem is recent work showing association
of BP and hypertension with two common SNPs in the NPPA
and  NPPB gene cluster encoding the atrial natriuretic
peptide (ANP) and the brain natriuretic peptide (BNP) [24].
The association with plasma levels of these peptides was first
established using the FHS cohort. Using this intermediate
trait, the authors then used a Mendelian randomization
approach to show that these SNPs predicted systolic BP
(SBP) and diastolic BP (DBP), as well as the incidence of
hypertension across several cohorts totaling >30,000
subjects. However, the effect size was small (minor alleles of
rs5068 and rs198358 explained 0.9-1.5 mmHg for SBP and
0.3-0.8 mmHg for DBP) and the SNPs are in the 3’-
untranslated region, so how they functionally affect
expression of the NPPA/B genes is unclear. There was also
an interesting lesson in that the researchers initially found a
non-synonymous SNP in the coding region that strongly
associated with ANP levels. However, this turned out to be
an artifact because it changed an amino acid in the amino-
terminal end of the pro-peptide that was measured by their
original assay kit. The effect disappeared when they used a
kit measuring mature peptide lacking this amino-terminal
pro-sequence.
The report from Newton-Cheh et al. [24] highlights the
effort required to robustly explore just a single susceptibility
locus for hypertension. Taking forward hits from the recent
GWAS calls for very large sample sizes (in the approximately
100K range or perhaps beyond), which may not be practical
or financially viable and thus suggests that other strategies
are needed. The use of pathway analysis reported recently by
Torkamani et al. is one such strategy [25]. Using the SNP
P-values from the WTCCC to weight >15,000 genes, they
generated gene networks that suggested pathogenic path-
ways for the common diseases in the WTCCC. Many of these
were biologically very plausible and interconnected, but
often not the ‘usual suspects’ in terms of candidate gene lists.
For example, for hypertension, the most over-represented
pathway was glutamate-regulated signaling through the D1A
receptor. Many of the other hypertension pathways had
significant overlap with those identified for CAD. This is not
surprising, but emphasizes that we should expect extensive
overlap in the risk alleles for the two diseases. Pathway
analysis is definitely a technique to watch.
U Us si in ng g   G GW WA AS S   t to o   p pr re ed di ic ct t   i in nd di iv vi id du ua al l   r re es sp po on ns se e   t to o
a an nt ti ih hy yp pe er rt te en ns si iv ve e   t th he er ra ap py y   a an nd d   t th he e   r ri is sk k   o of f   a ad dv ve er rs se e   d dr ru ug g
r re ea ac ct ti io on ns s
The large variation in individual BP responses to anti-
hypertensive drugs is a significant clinical problem, and
being able to predict this would be an enormous aid to
treatment optimization. Part of the variation can be ex-
plained by factors such as age, sex, ethnicity and renin
status. Common polymorphisms in the CYP2D6 gene have
also been important historically in determining the phar-
macokinetics of some antihypertensive drugs (for example,
debrisoquine and beta-blockers such as metoprolol), but the
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not affected by CYP2D6 metabolizer status. This implies that
a large proportion of the individual variability in drug
response is pharmacodynamic (that is, it involves the drug-
response pathway) and is genetically determined. The
genetics can of course be expected to be complex.
To date, genetic influences on the pharmacodynamics of
antihypertensive drug action have been studied in detail in
only a few cases. These include the indel in the ACE gene
and non-synonymous SNPs in the gene encoding the β1-
adrenoceptor, ADRB1. Plasma angiotensin-converting enzyme
(ACE) levels are regulated in part by the insertion/deletion
(I/D) polymorphism in intron 16 of the ACE gene, with DD
homozygotes having roughly twice the ACE levels of II
homozygotes [26]. However, there is no consensus on
whether this polymorphism affects either untreated BP or its
response to the introduction of an ACE inhibitor [27,28].
The situation with the non-synonymous SNPs in ADRB1 is
perhaps a little clearer. They affect the amino acids encoded
at positions 49 and 389, which substantially alters β1-
receptor function in vitro [29]. The fall in BP after dosing
with metoprolol is consistently predicted by the ADRB1
genotype, with carriers of an arginine at position 389
behaving as good responders [30,31]. However, there is no
consensus on the impact of these SNPs on the response of
the resting or exercise-induced heart rate to beta-blocker
therapy [32,33]. Exercise-induced heart rates are a robust
index of β1-receptor activation in vivo, so these differences
are probably attributable to patient selection and small
sample sizes.
The GWAS approach can be obviously applied to the
discovery of alleles that affect drug response, and several of
these are under way. For example, the PEAR study
(Pharmacogenomic Evaluation of Antihypertensive Res-
ponses) is part of the National Institutes of Health (NIH)
PharmacoGenomics Research Network [34], and is looking
for alleles that predict the BP response to a thiazide and
beta-blocker in a prospective cohort of 800 hypertensive
subjects [35]. This prospective study may seem large, but
from experience with GWAS it is probably only powered to
deliver modest to large allele effects. Its results are not
expected until 2010.
Predicting the short-term hemodynamic effect of an anti-
hypertensive drug is, of course, not the only goal. Since
hypertension treatment is initiated to prevent cardiovascular
end-points, it should be possible to predict these end-points
based on a patient’s genotype. A recent report based on the
outcome data in the INVEST (International Verapamil SR-
Trandolapril Study) antihypertension trial has successfully
done just this [36]. The authors were able to show that the
ADRB1  genotype predicted total mortality in a three-year
follow-up period, with the 49Ser-389Arg haplotype conferring
a significant hazard ratio of 3.7. Importantly, this risk was
only seen among subjects randomized to the non-beta-
blocker arm, while those randomized to the beta-blocker
arm (atenolol) had complete protection. In fact, phase III
hypertension drug trials are a potentially invaluable source
of outcome data for this sort of analysis, hence the interest in
submitting cohorts such as ASCOT (Anglo-Scandinavian
Cardiac Outcome Trial) to gene chip interrogation [37].
Thus, there is an expectation that we may soon have GWAS
data to address the task of identifying alleles that predict an
individual’s response to a given antihypertensive drug class
and treatment outcome. The task would be greatly helped if
there was some way of tapping into the mine of pharmaco-
genomic data collected at various stages of the preclinical
drug development process by the pharmaceutical industry.
Historically, these companies have been reluctant to give the
regulatory bodies sight of these data, although several years
ago the US Food and Drug Administration (FDA) stated the
data would not prejudice the drug registration process [38].
Nevertheless, a public safe-harbor and repository for these
data is still awaited.
We still have a very long way to go, but pharmacogenomics is
moving us closer to personalized prescribing of anti-
hypertensive drugs. We need to be able to identify the drugs
an individual is most likely to respond to as well as predict
the risk of adverse drug reactions (ADRs) to the same drugs.
The expectation is that this will increase compliance, which
remains a major obstacle to reducing many individuals’ BP
to internationally agreed target levels. The use of pharmaco-
genomic data to predict ADRs is evolving rapidly. There
have been some notable recent successes using the GWAS
approach - for example, in predicting individual risk of
myositis on statin therapy [39] or the risk of bradycardia
when using beta-blockers [40].
C Co on nc cl lu us si io on ns s
In the past year, landmark GWAS have appeared that
convincingly show the existence of susceptibility genes or
loci for essential hypertension. Many more are expected as
more datasets are meta-analyzed. Like other complex
diseases, the next hurdle will be to identify the functional
gene variants. This is a formidable task since it is likely that
many of these loci will be complex in their local operation as
well as in their interaction with other loci and the environ-
ment. However, they promise to provide novel insights into
the molecular pathways involved as well as new drug targets.
One of these has already been identified in the form of a
previously little known kinase called SPAK. However, in
terms of managing hypertension in the clinic we already
have enough ‘drugged’ BP targets. What is needed is a more
rational approach to using the drugs we have, and the
delivery of personalized medicine is the much-anticipated
spin-off from current GWAS research in this area. It remains
to be seen whether this improves on the current empirical
approaches such as the ‘ABCD’ rule [41].
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ACE, angiotensin-converting enzyme; ADR, adverse drug
reaction; ANP, atrial natriuretic peptide; ASCOT, Anglo-
Scandinavian Cardiac Outcome Trial; BP, blood pressure;
BRIGHT, BRItish Genetics of HyperTension; CAD, coronary
artery disease; CD-CV, common disease-common variant;
CHARGE, Cohorts for Heart and Aging Research in
Genomic Epidemiology; DBP, diastolic blood pressure; DCT,
distal convoluted tubule; FDA, Food and Drug Adminis-
tration; FHS, Framingham Heart Study; GWAS, genome-
wide association study/studies; I/D, insertion/deletion;
INVEST, International Verapamil SR-Trandolapril Study;
KORA, Kooperative Gesundheitsforschung in der Region
Augsburg; LD, linkage disequilibrium; NCCT, Na+/Cl– co-
transporter (SLC12A3); NIH, National Institutes of Health;
PEAR, Pharmacogenomic Evaluation of Antihypertensive
Responses; SBP, systolic blood pressure; SNP, single
nucleotide polymorphism; SPAK, STE20/SPS1-related
proline- and alanine-rich kinase; WNK, With No-lysine (=K)
kinase; WTCCC, Wellcome Trust Case Control Consortium.
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